for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biocartis Group NV

BCART.BR

Latest Trade

6.04EUR

Change

-0.01(-0.17%)

Volume

122,422

Today's Range

6.00

 - 

6.23

52 Week Range

5.40

 - 

12.52

As of on the Euronext Brussels ∙ Minimum 15 minute delay

Pricing

Previous Close
6.05
Open
6.09
Volume
122,422
3M AVG Volume
4.97
Today's High
6.23
Today's Low
6.00
52 Week High
12.52
52 Week Low
5.40
Shares Out (MIL)
51.36
Market Cap (MIL)
341.11
Forward P/E
-5.75
Dividend (Yield %)
--

Next Event

Biocartis Group NV Annual Shareholders Meeting

Latest Developments

More

Biocartis Updates On EUR 150 Mln Senior Unsecured Convertible Bonds

Biocartis Group Q3 Cash Position Up At 197 Million Euros

Biocartis Updates on Five Idylla Studies

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biocartis Group NV

Biocartis Group NV is a Belgium-based company, which specializes in the development of molecular diagnostic systems, especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.

Industry

Medical Equipment & Supplies

Contact Info

Generaal de Wittelaan 11B

+32.15.632600

https://biocartis.com/

Executive Leadership

Christian Reinaudo

Independent Chairman of the Board

Herman Verrelst

Chief Executive Officer, Executive Director

Ewoud Welten

Chief Financial Officer

Piet Houwen

Chief Operating Officer

Benoit Devogelaere

Chief Technology Officer

Key Stats

1.20 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-1.210

2017

-0.930

2018

-0.940

2019(E)

-1.093
Price To Earnings (TTM)
--
Price To Sales (TTM)
10.46
Price To Book (MRQ)
2.51
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
134.89
LT Debt To Equity (MRQ)
129.97
Return on Investment (TTM)
-25.97
Return on Equity (TTM)
-23.93

Latest News

Latest News

Biocartis partners with AstraZeneca on lung cancer diagnostics

Belgian molecular diagnostics company Biocartis Group <BCART.BR> said on Thursday it had entered into an agreement with British drugmaker AstraZeneca <AZN.L> to obtain faster lung cancer molecular diagnostic biomarker results in Europe.

BRIEF-Biocartis FY Total Operating Income Up At 23.1 Million Euros

* FY TOTAL OPERATING INCOME: EQUALED EUR 23.1M IN 2017 COMPARED TO EUR 13.8M IN 2016,

BRIEF-The EU Provides Biocartis With Up To 24 Million Euros Debt For Infectious Disease Projects

* REG-BIOCARTIS GROUP NV: EUROPEAN UNION PROVIDES BIOCARTIS WITH UP TO EUR 24M DEBT FINANCING FACILITY FOR INFECTIOUS DISEASE PROJECTS

BRIEF-Biocartis And Amgen Sign New Agreement

* REG-BIOCARTIS GROUP NV: BIOCARTIS AND AMGEN SIGN NEW COMPANION DIAGNOSTIC AGREEMENT FOR NOVEL ONCOLOGY COMPOUND

BRIEF-Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests

* BIOCARTIS AND AMGEN SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS

BRIEF-Biocartis Raises 80 Million Dollars

* ANNOUNCED ON TUESDAY THAT IT RAISED EUR 80 MILLION IN GROSS PROCEEDS

BRIEF-Bookrunner says Biocartis Group deal upsized to 80 mln euros From 60 mln euros base deal size

* BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS DEAL UPSIZED TO 80 MILLION EUROS FROM 60 MILLION EUROS BASE DEAL SIZE

BRIEF-Biocartis Share Offering Of Up To About 8.9 mln Shares - bookrunner

* SAYS OFFERING DEAL SIZE ABOUT 60 MILLION EUROS Further company coverage:

BRIEF-Biocartis Launches Equity Placement

* REG-BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES EQUITY PLACEMENT

BRIEF-Biocartis Group Launches Liquid Biopsy Tests with Merck

* TESTS DEVELOPED UNDER PARTNERSHIP WITH MERCK KGAA, DARMSTADT, GERMANY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biocartis Group sees ‍2017 guidance reiterated

* CASH POSITION AT END OF Q3 2017 AMOUNTED TO APPROXIMATELY EUR 56 MILLION (UNAUDITED FIGURE) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Genomic Health and Biocartis announce agreement to develop a breast cancer test

* GENOMIC HEALTH AND BIOCARTIS ANNOUNCE AGREEMENT TO DEVELOP AN IDYLLA(TM) IVD ONCOTYPE DX(®) BREAST CANCER TEST TO BROADEN GLOBAL PATIENT ACCESS

BRIEF-Biocartis H1 total operating income up at 6.8 million euros

* H1 TOTAL OPERATING INCOME EUR 7.0 MILLION VERSUS EUR 6.8 MILLION YEAR AGO

BRIEF-Biocartis' Idylla respiratory panel receives clearance by FDA

* REG-BIOCARTIS GROUP NV: IDYLLA(TM) RESPIRATORY (IFV-RSV) PANEL RECEIVES 510(K) CLEARANCE BY US FDA Source text: http://bit.ly/2vGWUK1 Further company coverage: (Gdynia Newsroom)

BRIEF-Biocartis: strong performance data of proprietary MSI biomarkers for Idylla MSI test to be published at ESMO

* REG-BIOCARTIS GROUP NV: STRONG PERFORMANCE DATA OF PROPRIETARY MSI BIOMARKERS FOR THE IDYLLA(TM) MSI TEST TO BE PUBLISHED AT ESMO Source text for Eikon: http://bit.ly/2eGN2p8 Further company coverage: (Gdynia Newsroom)

BRIEF-Biocartis' Idylla Instrument and Idylla Console exempt from FDA 510(k) notification requirements

* REG-BIOCARTIS GROUP NV: BIOCARTIS' IDYLLA(TM) INSTRUMENT AND IDYLLA(TM) CONSOLE EXEMPT FROM US FDA 510(K) NOTIFICATION REQUIREMENTS

BRIEF-Biocartis and A*Star's ETPL initiate development of breast cancer assay

* BIOCARTIS GROUP NV: BIOCARTIS AND A*STAR'S ETPL INITIATE DEVELOPMENT OF BREAST CANCER ASSAY TO GUIDE THERAPY SELECTION SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE: (Gdynia Newsroom:)

BRIEF-Biocartis Group launches CE-marked IVD test for lung cancer

* BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES CE-MARKED IVD TEST FOR LUNG CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biocartis Group and MRC Technology initiate development of liquid biopsy test for breast cancer

* REG-BIOCARTIS GROUP NV: MRC TECHNOLOGY AND BIOCARTIS INITIATE DEVELOPMENT OF LIQUID BIOPSY TEST FOR BREAST CANCER

BRIEF-Biocartis Group launches CE-marked IVD NRAS test for colorectal cancer

* REG-BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES CE-MARKED IVD NRAS TEST FOR COLORECTAL CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up